Ferreira-González Ignacio, Busse Jason W, Heels-Ansdell Diane, Montori Victor M, Akl Elie A, Bryant Dianne M, Alonso-Coello Pablo, Alonso Jordi, Worster Andrew, Upadhye Suneel, Jaeschke Roman, Schünemann Holger J, Permanyer-Miralda Gaietà, Pacheco-Huergo Valeria, Domingo-Salvany Antònia, Wu Ping, Mills Edward J, Guyatt Gordon H
Departament de Medicina, Universitat Autònoma de Barcelona, and Hospital Vall d'Hebron, Barcelona 08035, Spain.
BMJ. 2007 Apr 14;334(7597):786. doi: 10.1136/bmj.39136.682083.AE. Epub 2007 Apr 2.
To explore the extent to which components of composite end points in randomised controlled trials vary in importance to patients, the frequency of events in the more and less important components, and the extent of variability in the relative risk reductions across components.
Systematic review of randomised controlled trials.
Cardiovascular randomised controlled trials published in the Lancet, Annals of Internal Medicine, Circulation, European Heart Journal, JAMA, and New England Journal of Medicine, from 1 January 2002 to 30 June 2003. Component end points of composite end points were categorised according to importance to patients as fatal, critical, major, moderate, or minor.
Of 114 identified randomised controlled trials that included a composite end point of importance to patients, 68% (n=77) reported complete component data for the primary composite end point; almost all (98%; n=112) primary composite end points included a fatal end point. Of 84 composite end points for which component data were available, 54% (n=45) showed large or moderate gradients in both importance to patients and magnitude of effect across components. When analysed by categories of importance to patients, the most important components were associated with lower event rates in the control group (medians of 3.3-3.7% for fatal, critical, and major outcomes; 12.3% for moderate outcomes; and 8.0% for minor outcomes). Components of greater importance to patients were associated with smaller treatment effects than less important ones (relative risk reduction of 8% for death and 33% for components of minor importance to patients).
The use of composite end points in cardiovascular trials is frequently complicated by large gradients in importance to patients and in magnitude of the effect of treatment across component end points. Higher event rates and larger treatment effects associated with less important components may result in misleading impressions of the impact of treatment.
探讨随机对照试验中复合终点的各个组成部分对患者的重要性差异程度、重要性较高和较低的组成部分中的事件发生频率,以及各组成部分相对风险降低的变异性程度。
对随机对照试验进行系统评价。
2002年1月1日至2003年6月30日发表在《柳叶刀》《内科学年鉴》《循环》《欧洲心脏杂志》《美国医学会杂志》和《新英格兰医学杂志》上的心血管随机对照试验。复合终点的组成终点根据对患者的重要性分为致命、危急、主要、中度或次要。
在114项确定的包含对患者重要的复合终点的随机对照试验中,68%(n = 77)报告了主要复合终点的完整组成数据;几乎所有(98%;n = 112)主要复合终点都包含一个致命终点。在84个有组成数据的复合终点中,54%(n = 45)在对患者的重要性和各组成部分的效应大小方面显示出大或中等程度的梯度。按对患者的重要性类别分析时,最重要的组成部分与对照组中较低的事件发生率相关(致命、危急和主要结局的中位数为3.3 - 3.7%;中度结局为12.3%;次要结局为8.0%)。对患者更重要的组成部分与比不太重要的组成部分更小的治疗效果相关(死亡的相对风险降低8%,对患者不太重要的组成部分为33%)。
在心血管试验中使用复合终点常常因各组成终点对患者的重要性以及治疗效果大小存在较大梯度而变得复杂。与不太重要的组成部分相关的较高事件发生率和较大治疗效果可能会导致对治疗影响产生误导性印象。